<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438841</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000536219</org_study_id>
    <secondary_id>FHCRC-2123.00</secondary_id>
    <nct_id>NCT00438841</nct_id>
  </id_info>
  <brief_title>Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma</brief_title>
  <official_title>A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and&#xD;
      dexamethasone, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells&#xD;
      by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide,&#xD;
      dexamethasone, and thalidomide may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with&#xD;
      cyclophosphamide, dexamethasone, and thalidomide works in treating patients with newly&#xD;
      diagnosed, previously untreated multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with newly diagnosed, previously untreated&#xD;
           multiple myeloma treated with bortezomib, cyclophosphamide, dexamethasone, and&#xD;
           thalidomide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV on days 1, 4, 8, and 11; cyclophosphamide IV on days 1 and 8&#xD;
      of courses 1-3; oral thalidomide once daily on days 1-21 beginning in course 4; and&#xD;
      dexamethasone IV or orally once daily on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats&#xD;
      every 21 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 43 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma meeting 1 of the following criteria:&#xD;
&#xD;
               -  Monoclonal immunoglobulin spike on serum electrophoresis (IgG &gt; 3.5 g/dL or IgA &gt;&#xD;
                  2.0 g/dL) and kappa or lambda light chain excretion &gt; 1 g/day by 24-hour urine&#xD;
                  protein electrophoresis AND meets any of the following criteria:&#xD;
&#xD;
                    -  Bone marrow plasmacytosis (10-30% plasma cells)&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
               -  Monoclonal immunoglobulin of lesser magnitude present and bone marrow&#xD;
                  plasmacytosis (10-30% plasma cells) AND meets any of the following criteria:&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
                    -  IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL&#xD;
&#xD;
               -  Bone marrow plasmacytosis (&gt; 30% plasma cells) or plasmacytoma on tissue biopsy&#xD;
                  AND meets any of the following criteria:&#xD;
&#xD;
                    -  Monoclonal immunoglobulin of lesser magnitude present&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
                    -  IgM &lt; 50 mg/dL, IgA &lt; 100 mg/dL, or IgG &lt; 600 mg/dL&#xD;
&#xD;
               -  FreeLite testing abnormal and kappa:lambda light chain ratio abnormal&#xD;
&#xD;
          -  Symptomatic disease requiring treatment&#xD;
&#xD;
               -  Documented related organ or tissue involvement, if present&#xD;
&#xD;
          -  Measurable disease, defined as 1 of the following:&#xD;
&#xD;
               -  Monoclonal immunoglobulin spike on serum electrophoresis ≥ 1 g/dL and/or urine&#xD;
                  monoclonal immunoglobulin spike ≥ 200 mg/day&#xD;
&#xD;
               -  Abnormal FreeLite testing (for nonsecretors)&#xD;
&#xD;
               -  Patients with nonsecretory disease must meet either of the following criteria for&#xD;
                  measurability:&#xD;
&#xD;
                    -  Has measurable protein by FreeLite testing&#xD;
&#xD;
                    -  Untreated soft tissue plasmacytoma and/or evaluable disease in bone marrow&#xD;
&#xD;
          -  Newly diagnosed, previously untreated disease&#xD;
&#xD;
          -  No POEMS syndrome (i.e., plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein [M-protein], and skin changes)&#xD;
&#xD;
          -  No plasma cell leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 50-100%&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (≥ 50,000/mm³ if bone marrow is extensively infiltrated)&#xD;
&#xD;
               -  Extensive infiltration is defined as &gt; 50% myeloma cells or plasma cells&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN (unless clearly related to the disease)&#xD;
&#xD;
          -  Creatinine clearance ≥ 20 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 methods of effective contraception ≥ 4 weeks prior to&#xD;
             beginning treatment, during, and for ≥ 4 weeks after completion of study treatment&#xD;
&#xD;
          -  No impaired kidney function requiring dialysis&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No known active hepatitis B or C&#xD;
&#xD;
          -  No cardiovascular disease including, but not limited to, any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class II-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Severe uncontrolled ventricular arrhythmias&#xD;
&#xD;
               -  Clinically significant pericardial disease&#xD;
&#xD;
               -  Acute ischemic or active conduction system abnormalities by EKG&#xD;
&#xD;
          -  No history of allergic reactions to compounds containing mannitol, bortezomib, or&#xD;
             cyclophosphamide&#xD;
&#xD;
          -  No second malignancy requiring concurrent treatment&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy, immunotherapy, vaccine therapy, therapeutic doses of steroids,&#xD;
             or other agents for the treatment of active myeloma&#xD;
&#xD;
               -  Drugs given to prevent onset of myeloma allowed&#xD;
&#xD;
               -  Bisphosphonates for hypercalcemia or short course corticosteroids for&#xD;
                  hypercalcemia or cord compromise allowed&#xD;
&#xD;
          -  Prior local radiotherapy with or without a brief exposure to steroids allowed&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
               -  Spot radiotherapy to ≤ 3 vertebrae allowed&#xD;
&#xD;
          -  No concurrent steroids at &gt; 10 mg of prednisone daily (or the equivalent) for other&#xD;
             medical conditions (e.g., asthma, systemic lupus erythematosus, or rheumatoid&#xD;
             arthritis)&#xD;
&#xD;
          -  No other concurrent chemotherapy or investigational agents&#xD;
&#xD;
          -  Concurrent daily acetylsalicylic acid required during course 4-6 of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I. Bensinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates Summit Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Regional Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Comprehensive Cancer Center - Manhattan</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lone Star Oncology - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <last_update_submitted>March 12, 2009</last_update_submitted>
  <last_update_submitted_qc>March 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Phyllis Potts</name_title>
    <organization>Aptium Oncology</organization>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

